A mitochondrial enzyme drives chemotherapy heart damage by leaking damaged DNA — and a vitamin coenzyme blocked it, in mice

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Cardio-oncology has a precise problem: a drug that works against tumors also wounds the heart, through mitochondria. This paper names the whole chain — enzyme, damaged mitochondrial DNA, inflammatory trigger — and shows a common vitamin coenzyme interrupting it in mice. A named chain with a named blocker is exactly what a field needs to design the human experiments that have not happened yet.

What exactly did the team find?

CMPK2 is a mitochondrial nucleotide-metabolism enzyme. In doxorubicin-injured mouse hearts, CMPK2 expression was significantly upregulated, driven by the transcription factor STAT1. The study reports that CMPK2 promoted oxidative damage to mitochondrial DNA and the leakage of that DNA into the cytosol, where it activated the NLRP3 inflammasome. Using heart-muscle-specific CMPK2 knockout and overexpression models, plus AAV9 cardiac gene delivery in vivo and molecular assays in vitro, the team showed the enzyme is not a bystander: its level tracks, and changes, the injury.

What did FAD do in the experiments?

Flavin adenine dinucleotide — FAD, the coenzyme cells build from riboflavin (vitamin B2) and a core carrier in mitochondrial energy metabolism — was administered in the mouse model and mitigated doxorubicin-induced cardiac injury without compromising the drug's antitumor efficacy. That selectivity is the result that matters: a heart protectant that blunts chemotherapy would be a trade no oncologist wants. The authors conclude that targeting the CMPK2–mtDNA–NLRP3 axis with FAD is a promising cardio-oncology strategy, while the findings remain preclinical.

What are the limits readers should keep?

All of it is mice and cell assays. Mouse doxorubicin cardiotoxicity models approximate, but do not reproduce, the years-long cardiac risk in human cancer survivors; FAD dosing, delivery and safety as a cardioprotective adjunct in people are untested; and whether CMPK2 behaves the same way in human heart tissue is unknown. The honest label is a strong mechanistic lead with a plausible, inexpensive candidate blocker — the starting line for translational work, not a reason for any patient to change anything about chemotherapy or vitamin intake without their oncology team.

Where the evidence stands

• Established: Doxorubicin causes dose-dependent cardiotoxicity; mitochondrial DNA leaking into the cytosol can activate the NLRP3 inflammasome; and FAD is the riboflavin-derived coenzyme central to mitochondrial redox reactions.
• Preliminary: In mouse and cell models (Cellular & Molecular Biology Letters, Oct 29, 2026; DOI 10.1186/s11658-026-01025-4), STAT1-driven CMPK2 upregulation mediated doxorubicin heart injury via oxidative mtDNA damage, leakage and NLRP3 activation, and FAD administration mitigated the injury without reducing antitumor efficacy.
• Absent: Any human data — CMPK2 behavior in human hearts, FAD as a cardioprotective adjunct in patients, dosing, safety or outcomes.